Endocyte, Inc. (ECYT) Expected to Announce Earnings of -$0.21 Per Share
Brokerages predict that Endocyte, Inc. (NASDAQ:ECYT) will post earnings of ($0.21) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Endocyte’s earnings, with estimates ranging from ($0.23) to ($0.19). Endocyte also reported earnings of ($0.21) per share in the same quarter last year. The firm is expected to report its next quarterly earnings report on Wednesday, November 8th.
On average, analysts expect that Endocyte will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($0.97) to ($0.89). For the next fiscal year, analysts expect that the firm will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.82) to ($0.80). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Endocyte.
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03). Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. The company had revenue of $0.01 million for the quarter. During the same period in the previous year, the firm earned ($0.25) EPS.
Several research analysts have recently commented on the company. Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine lowered Endocyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 3rd. Wedbush lowered Endocyte from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $2.00 in a research report on Monday, June 5th. Finally, Cowen and Company lowered Endocyte from an “outperform” rating to a “market perform” rating in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $3.58.
Shares of Endocyte (ECYT) traded down 0.71% during trading on Friday, hitting $1.40. The stock had a trading volume of 128,623 shares. The company’s market cap is $59.61 million. The stock has a 50-day moving average price of $1.36 and a 200 day moving average price of $1.88. Endocyte has a 12 month low of $1.17 and a 12 month high of $3.49.
A number of large investors have recently made changes to their positions in ECYT. Stifel Financial Corp increased its position in Endocyte by 3.9% during the 1st quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,711 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Endocyte by 34.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 25,003 shares in the last quarter. Teachers Advisors LLC increased its position in Endocyte by 17.1% during the 4th quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 9,506 shares in the last quarter. Spark Investment Management LLC acquired a new position in Endocyte during the 2nd quarter valued at about $177,000. Finally, LMR Partners LLP acquired a new position in Endocyte during the 2nd quarter valued at about $196,000. 28.80% of the stock is currently owned by institutional investors.
Endocyte Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related stocks with our FREE daily email newsletter.